# Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

> **NCT01753401** · PHASE4 · COMPLETED · sponsor: **Mallinckrodt** · enrollment: 38 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Acthar
- **DRUG:** Placebo
- **DRUG:** Steroid Drug

## Key facts

- **NCT ID:** NCT01753401
- **Lead sponsor:** Mallinckrodt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753401, "Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01753401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*